New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

Being overweight raises your risk of thyroid cancer ... One study reported that the incidence of thyroid cancer in semaglutide-treated patients was less than 1%. As of now, the FDA warning ...

The following text highlights some of these precautions. Boxed warning: Risk of thyroid cancer Semaglutide (the active ingredient in Ozempic and Wegovy) has a boxed warning for a possible risk of ...

A recent survey reveals the foods that people are less likely to eat once they start taking GLP-1 medications like Ozempic.

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

Semaglutide also delays gastric emptying ... but the label indicates thyroid cancer risk. Contraindications include a personal or family history of medullary thyroid carcinoma (MTC) or multiple ...

A new analysis of FDA adverse event reports suggests a potential link between tirzepatide and thyroid cancer. Learn what this ...

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...

which investigated more than 16,000 patients over a period of six years, raised ocular safety issues related to semaglutide. The study found that the medicine can potentially increase the risk of ...

Semaglutide use associated with increased risk for NAION at the 2-, 3-, and 4-year time point from the index date.